These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 9543466)

  • 1. Preclinical pharmacology of metrifonate.
    Jann MW
    Pharmacotherapy; 1998; 18(2 Pt 2):55-67; discussion 79-82. PubMed ID: 9543466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating response to metrifonate.
    Tariot PN
    J Clin Psychiatry; 1998; 59 Suppl 9():33-7. PubMed ID: 9720485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of food and time of administration on the pharmacokinetic and pharmacodynamic profile of metrifonate.
    Heinig R; Sachse R
    Int J Clin Pharmacol Ther; 1999 Sep; 37(9):456-64. PubMed ID: 10507245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metrifonate: overview of safety and efficacy.
    Cummings JL
    Pharmacotherapy; 1998; 18(2 Pt 2):43-6; discussion 79-82. PubMed ID: 9543464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, pharmacodynamics, and safety of metrifonate in patients with Alzheimer's disease.
    Pettigrew LC; Bieber F; Lettieri J; Wermeling DP; Schmitt FA; Tikhtman AJ; Ashford JW; Smith CD; Wekstein DR; Markesbery WR; Orazem J; Ruzicka BB; Mas J; Gulanski B
    J Clin Pharmacol; 1998 Mar; 38(3):236-45. PubMed ID: 9549662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metrifonate: a new agent for the treatment of Alzheimer's disease.
    Williams BR
    Am J Health Syst Pharm; 1999 Mar; 56(5):427-32. PubMed ID: 10096702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group.
    Raskind MA; Cyrus PA; Ruzicka BB; Gulanski BI
    J Clin Psychiatry; 1999 May; 60(5):318-25. PubMed ID: 10362441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of long-term treatment with metrifonate, a cholinesterase inhibitor, on cholinergic activity, amyloid pathology, and cognitive function in APP and PS1 doubly transgenic mice.
    Liu L; Ikonen S; Heikkinen T; Tapiola T; van Groen T; Tanila H
    Exp Neurol; 2002 Feb; 173(2):196-204. PubMed ID: 11822883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transdermal patch delivery of acetylcholinesterase inhibitors.
    Moriearty PL; Thornton SL; Becker RE
    Methods Find Exp Clin Pharmacol; 1993; 15(6):407-12. PubMed ID: 8231460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of metrifonate on extracellular brain acetylcholine and object recognition in aged rats.
    Scali C; Giovannini MG; Bartolini L; Prosperi C; Hinz V; Schmidt B; Pepeu G
    Eur J Pharmacol; 1997 May; 325(2-3):173-80. PubMed ID: 9163564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metrifonate treatment enhances acquisition of eyeblink conditioning in aging rabbits.
    Kronforst-Collins MA; Moriearty PL; Ralph M; Becker RE; Schmidt B; Thompson LT; Disterhoft JF
    Pharmacol Biochem Behav; 1997 Jan; 56(1):103-10. PubMed ID: 8981616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacological basis for metrifonate's favourable tolerability in the treatment of Alzheimer's disease.
    Schmidt BH; Heinig R
    Dement Geriatr Cogn Disord; 1998; 9 Suppl 2():15-9. PubMed ID: 9718230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Seizures in patients receiving concomitant antimuscarinics and acetylcholinesterase inhibitor.
    Piecoro LT; Wermeling DP; Schmitt FA; Ashford JW
    Pharmacotherapy; 1998; 18(5):1129-32. PubMed ID: 9758325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical trial protocol of the Metrifonate in Alzheimer's Trial (MALT).
    McKeith IG
    Dement Geriatr Cogn Disord; 1998; 9 Suppl 2():2-7. PubMed ID: 9718228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of metrifonate, a cholinesterase inhibitor, on local cerebral glucose utilization in young and aged rats.
    Bassant MH; Jazat-Poindessous F; Lamour Y
    J Cereb Blood Flow Metab; 1996 Sep; 16(5):1014-25. PubMed ID: 8784247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognitive and metabolic responses to metrifonate therapy in Alzheimer disease.
    Mega MS; Cummings JL; O'Connor SM; Dinov ID; Reback E; Felix J; Masterman DL; Phelps ME; Small GW; Toga AW
    Neuropsychiatry Neuropsychol Behav Neurol; 2001 Jan; 14(1):63-8. PubMed ID: 11234910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metrifonate therapy in Alzheimer's disease: a pooled analysis of four randomized, double-blind, placebo-controlled trials.
    Farlow MR; Cyrus PA
    Dement Geriatr Cogn Disord; 2000; 11(4):202-11. PubMed ID: 10867446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of metrifonate, its transformation product dichlorvos, and other organophosphorus and reference cholinesterase inhibitors on Morris water escape behavior in young-adult rats.
    van der Staay FJ; Hinz VC; Schmidt BH
    J Pharmacol Exp Ther; 1996 Aug; 278(2):697-708. PubMed ID: 8768721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metrifonate: update on a new antidementia agent.
    Ringman JM; Cummings JL
    J Clin Psychiatry; 1999 Nov; 60(11):776-82. PubMed ID: 10584768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The recovery of cerebrospinal fluid acetylcholinesterase activity in Alzheimer's disease patients after treatment with metrifonate.
    Unni L; Vicari S; Moriearty P; Schaefer F; Becker R
    Methods Find Exp Clin Pharmacol; 2000; 22(1):57-61. PubMed ID: 10791297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.